首页|阿奇霉素联合孟鲁司特钠治疗小儿肺炎支原体肺炎的疗效分析

阿奇霉素联合孟鲁司特钠治疗小儿肺炎支原体肺炎的疗效分析

扫码查看
目的 探讨阿奇霉素联合孟鲁司特钠治疗小儿肺炎支原体肺炎(mycoplasmal pneumonia,MPP)的疗效.方法 方便选取2023年3月—2024年3月巨野县中医医院收治的74例小儿MPP患儿作为研究对象,以不同的治疗方法分为A组、B组,各37例.A组予以阿奇霉素序贯治疗,B组在A组的基础上联合孟鲁司特钠治疗,对比两组治疗总有效率、药物不良反应、症状消失时间、炎性因子及免疫功能.结果 B组治疗总有效率为97.30%(36/37),高于A组的78.38%(29/37),差异有统计学意义(χ2=4.554,P<0.05).B组发热、喘憋、咳嗽及肺啰音症状消失时间均短于A组,差异有统计学意义(P均<0.05).B组降钙素原、C-反应蛋白、免疫球蛋白E及免疫球蛋白G水平均低于A组,免疫球蛋白A水平高于A组,差异有统计学意义(P均<0.05).B组药物不良反应总发生率为10.81%(4/37),高于A组的8.11%(3/37),但差异无统计学意义(χ2=0.000,P>0.05).结论 使用阿奇霉素和孟鲁司特钠联合治疗儿童MPP能显著增强疗效,缩短症状恢复时间,并对炎症因素与免疫指标改善产生积极效果,同时拥有较低药物不良反应发生率.
Efficacy Analysis of Azithromycin Combined with Montelukast Sodium in the Treatment of Mycoplasma Pneumoniae Pneumonia in Children
Objective To investigate the efficacy of azithromycin combined with Montelukast sodium in the treatment of mycoplasmal pneumonia(MPP)in children.Methods A total of 74 children with MPP admitted to Juye County Hos-pital of Traditional Chinese Medicine from March 2023 to March 2024 were conveniently selected as study objects and divided into group A and group B by differnet therapeutic methods,with 37 cases in each group.Group A was treated with azithromycin sequential therapy,and group B was treated with montelukast sodium on the basis of group A.The total effective rate,adverse drug reactions,symptom disappearance time,inflammatory factors and immune function were compared between the two groups.Results The total effective rate of group B was 97.30%(36/37),which was higher than 78.38%(29/37)of group A,and the difference was statistically significant(χ2=4.554,P<0.05).The disappearance time of fever,wheezing,cough and pulmonary rales in group B were all shorter than that in group A,and the differences were statistically significant(all P<0.05).The levels of procalcitonin,C-reactive protein,immu-noglobulin E and immunoglobulin G in group B were lower than those in group A,and the level of immunoglobulin A was higher than that in group A the the differences were statistically significant(all P<0.05).The total adverse drug re-action in group B was 10.81%(4/37),which was higher than 8.11%(3/37)of group A,but the difference was not statis-tically significant(χ2=0.000,P>0.05).Conclusion The combination of azithromycin and montelukast sodium in the treatment of MPP in children can significantly enhance the curative effect,shorten the recovery time of symptoms,and have a positive effect on the improvement of inflammatory factors and immune indexes,and have a lower adverse drug reaction rate.

AzithromycinMontelukast sodiumMycoplasma pneumonia in childrenInflammatory factorsImmune function

关爱丽

展开 >

巨野县中医医院儿科,山东 巨野 274900

阿奇霉素 孟鲁司特钠 小儿肺炎支原体肺炎 炎性因子 免疫功能

2024

中外医疗
卫生部医院管理研究所 二十一世纪联合创新医药科学研究院

中外医疗

影响因子:0.909
ISSN:1674-0742
年,卷(期):2024.43(21)